研究单位：[1]LaNova Medicines Limited[2]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China[3]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China[4]Linyi Cancer Hospital,Linyi,Shandong,China[5]Beijing Tongren Hospital, CMU,Beijing,China[6]Fudan University Shanghai Cancer Center,Shanghai,China
研究目的：
This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
